Eli Lilly and Company has updated label of its once-weekly Trulicity (dulaglutide) to include use in combination with basal insulin for adults with Type 2 diabetes.
Prexton Therapeutics has closed a €29m Series B round led by Forbion Capital Partners and Seroba Life Sciences.
The US Federal Trade Commission (FTC) has charged that Shire ViroPharma abused government processes via serial, sham petitioning to delay generics and maintain its monopoly over Vancocin HCl Capsules.
Acticor Biotech, a bio-pharmaceutical company focused on the treatment of acute ischemic stroke, has raised €1,5m from CapDecisif Management.
Biotechnology company Chondrial Therapeutics, focused on the treatment of rare mitochondrial diseases, has secured up to $22.6m in Series A financing led by Deerfield Management besides naming a new president and CEO in Carole Ben-Maimon, MD.
Soligenix has secured Promising Innovative Medicine (PIM) designation from the UK Medicines and Healthcare Products Regulatory Agency for SGX301 (synthetic hypericin) to treat cutaneous T-cell lymphoma (CTCL).
Tarveda Therapeutics has raised $30m in series D financing to advance pentarin miniaturized drug conjugates.
Neurotrope has signed a licensing agreement with Stanford University for an accelerated synthesis of Alzheimer's drug bryostatin-1.
Biscayne Pharmaceuticals has raised financing for its new spin-out, Biscayne Neurotherapeutics, which was recently established to develop its biopharmaceutical assets for the treatment of neurological disorders.
Cellestia Biotech has raised CHF8m in funding from private investors and PPF Group to advance its lead anti-cancer compound CB-103 to clinical development stage.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.